CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Details for Australian Patent Application No. 2005300315 (hide)

Owner Pfizer Products Inc.

Inventors Gomez-Navarro, Jesus

Agent Shelston IP

Pub. Number AU-A-2005300315

PCT Pub. Number WO2006/048749

Priority 60/624,856 04.11.04 US

Filing date 24 October 2005

Wipo publication date 11 May 2006

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

Event Publications

3 May 2007 PCT application entered the National Phase

  PCT publication WO2006/048749 Priority application(s): WO2006/048749

26 May 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005300317-Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]- 3-E-[2-(pyridin-2-yl)ethenyl]indazole

2005300313-Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound